Revised forecast
Fiscal year ending May 2027 · Second quarter (interim period)Previous forecast published 14 July 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Sales of imported active pharmaceutical ingredients in the pharmaceutical business exceeded expectations, and some sales of ion-exchange resins in the chemicals business were brought forward. In addition, sales of high-value-added products progressed well amid a recovery in the semiconductor-related market, and the company also captured temporary demand.
| Item | Details |
|---|---|
| Net Sales | ¥3,300 million → ¥3,500 million（+6.1%） |
| Operating profit | ¥150 million → ¥250 million（+66.7%） |
| Ordinary income | ¥120 million → ¥240 million（+100.0%） |
| Profit attributable to owners of the parent | ¥90 million → ¥160 million（+77.8%） |
| Net income per share | 22.4 yen and sen → 39.75 yen and sen |
| Fiscal Period Covered | Fiscal year ending May 2027 |
| Period Covered | Second quarter (interim period) |
| Publication date of previous forecast | 14 July 2026 |
| Previous-period results | Net sales: ¥3,681 million; operating profit: ¥349 million; ordinary profit: ¥336 million; interim net profit: ¥224 million; interim net profit per share: ¥60.85 |
| Reason for the revision | Sales of imported active pharmaceutical ingredients in the pharmaceutical business exceeded expectations, and some sales of ion-exchange resins in the chemicals business were brought forward. In addition, sales of high-value-added products progressed well amid a recovery in the semiconductor-related market, and the company also captured temporary demand. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of imported active pharmaceutical ingredients in the pharmaceutical business, particularly active pharmaceutical ingredients for antiepileptic and anti-herpesvirus drugs, exceeded expectations; some sales of ion-exchange resins in the chemicals business were brought forward; sales of high-value-added products progressed well amid a recovery in the semiconductor-related market; and the company captured temporary demand.